P130018/S006: ProACT Adjustable Continence Therapy for Men
FDA’s recorded scope: addition of a post-cure process to the manufacturing procedure for the implantable device component
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 3 FDA records to the applicant name Uromedica, Inc.. 2 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Oct 3, 2025 to Feb 11, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code EZY appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P130018, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 1840 Berkshire Ln. N., Plymouth, MN, 55441. Recorded on P130018/S006, decision dated Feb 11, 2026.
FDA’s recorded scope: addition of a post-cure process to the manufacturing procedure for the implantable device component
FDA’s recorded scope: for the addition of four potential adverse events and updates to the MRI Information section of the instructions for use
FDA’s recorded scope: Approval of the modifications to the study protocol including expansion of the study to 10-14 study sites and modifications to the Informed Consent Form for the post-approval study.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.